Jennifer Hagan is the Vice President of Quality at Strand Therapeutics, bringing more than 25 years of experience in Quality Assurance across the biopharmaceutical industry. She has successfully led Quality organizations from early clinical development through commercial launch, with a proven track record at both emerging biotech and global pharmaceutical companies. At Strand, Jennifer oversees the Quality Systems (QS), Quality Assurance (QA), and Quality Control (QC) functions. She is responsible for driving global GxP strategy, implementing phase-appropriate quality systems, managing vendor oversight, and ensuring inspection readiness.
Prior to joining Strand, Jenn held Quality leadership roles at Omega Therapeutics, Sage Therapeutics, Shire, and Sanofi. She is widely recognized for her pragmatic, risk-based approach to quality, as well as her deep technical expertise, strategic leadership, and strong commitment to continuous improvement. Jennifer holds a Bachelor of Science degree from the University of Massachusetts.
